Dr. John Cush RheumNow
1 year 9 months ago
RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE
Dr. John Cush RheumNow
1 year 9 months ago
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
1 year 9 months ago
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/DZrM5aQpJ7 https://t.co/CkGP6H8J6x
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes. Data from the SPACE cohort (abstract 0566), the ASAS-PerSpA study (abstract 0550) and the US Claims data (abstract 0558), allows us to highlight the barriers to early diagnosis of axSpA and identify opportunities for
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC. Here are some of the best abstracts from Saturday Nov. 16th. You can also spot these on Twitter by looking for the (#ACRbest) hashtag.
Richard Conway RichardPAConway
1 year 9 months ago
Real shame to see a fair few withdrawn oral presentations on #ACR24 schedule. Surely there is a better way? I'm sure a fellow would have loved to have the opportunity to present their project as an oral, even at short notice. @RheumNow
sheila RHEUMarampa
1 year 9 months ago
Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1
showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA
Again, effect of gender differences
@RheumNow #ACR24 abs599 https://t.co/2DPYC8exES
Brian Jaros, MD Dr_Brian_MD
1 year 9 months ago
New data to guide role of long-term, low dose GC in GPA
Active GPA s/p tx -> randomized to d/c pred within 1 mo or stay on 5mg daily
Fewer relapses on 5mg pred but w/qualifications:
👉 most flares = minor
👉 no difference in flares if RTX on board
@RheumNow #ACR24 Abst 0774 https://t.co/Jvc40QWLqM
TheDaoIndex KDAO2011
1 year 9 months ago
Come visit @rheumnow where #ACR24 #RheumEducation is distilled and disseminated. @uptoTate https://t.co/vzMeRL8307
Richard Conway RichardPAConway
1 year 9 months ago
Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow
Akhil Sood MD AkhilSoodMD
1 year 9 months ago
What is my risk of developing SLE?
Abstract 0843 highlights a predictive model that accurately classifies SLE risk using genetics, lifestyle, and environmental factors. Model 3 (genetics + environment + lifestyle) performed the best compared to models 1 and 2.
@RheumNow #ACR24 https://t.co/sk9oG0OY3W
Richard Conway RichardPAConway
1 year 9 months ago
Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx
Mrinalini Dey DrMiniDey
1 year 9 months ago
Should we screen new #PMR pts for #LVV?
Pts with PMR had lower risk of aortic complications vs #GCA & similar risk as gen pop
BUT if they developed GCA later, the risk was same as those with new GCA
➡️Screening recommended in new GCA but not PMR pts
Ab0859 #ACR24 @RheumNow https://t.co/HsHPGlt5A9
